SEC Form 4 · accession 0001415889-15-000169
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uli Hacksell
Officer — CEO · Director
Period of report
Jan 14, 2015
Accepted (ET)
Jan 16, 2015 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 14, 2015 | M | 30,000 | $2.00 | A | 30,000 | D | |
| Common Stock | Jan 14, 2015 | G | 30,000 | $0.00 | D | 0 | D | |
| Common Stock | Jan 14, 2015 | G | 30,000 | $0.00 | A | 145,549 | I | By Family Trust |
| Common StockF2 | Jan 14, 2015 | S | 30,000 | $33.981 | D | 115,549 | I | By Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.00 | Jan 14, 2015 | M | 30,000 | D | — | Oct 19, 2018 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2014.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.68 to $34.33 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F350% of the shares subject to the stock option vested and became exercisable on October 20, 2010. The remaining shares vested in equal monthly installments over the following 2 years.